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Introduction
Atopic dermatitis (AD) affects 15–30% of children and 5% of 
adults and carries profound functional, psychological, and social 
morbidity1–3. Although mild and moderate AD can usually be 
managed with topical treatments and/or phototherapy, approxi-
mately 2% of people with AD require systemic treatments to 
induce adequate symptom control4,5.
We are entering an exciting era, described by some as a therapeu-
tic revolution6–8, as dozens of novel systemic treatments are being 
developed for AD. These targeted biologic and small molecule 
agents and the conventional systemic immunosuppressive AD 
treatments provide an increasingly broad range of therapeutic 
options. Although there is some clinical guidance on when to 
start systemic therapy, many evidence gaps remain regarding the 
comparative performance of these drugs9,10. Moreover, the lack of 
a gold standard conventional systemic therapy for AD means there 
is no benchmark against which to compare the performance of 
novel agents. Many factors, including the impact on disease sever-
ity and quality of life as well as adverse events (AEs) and cost- 
effectiveness, play into the complex treatment decision-making 
process when clinicians and patients agree on choosing a particu-
lar therapy and in the formulation of treatment guidance produced 
by stakeholders, such as the UK National Institute for Health and 
Care Excellence (NICE).
Based on a systematic search of the literature, we discuss the 
latest developments in systemic AD treatments. We present an 
indirect comparison of novel and conventional systemic AD 
treatments with regard to treatment efficacy, safety, and cost- 
effectiveness and highlight important gaps that need to be filled.
Conventional systemic atopic dermatitis treatments
The main conventional systemic treatments for AD are ciclosporin, 
methotrexate, and azathioprine11–13. Mycophenolate mofetil is less 
commonly used. Some of these agents have been used to treat severe 
AD for decades despite a lack of robust randomised controlled trial 
(RCT) evidence. Ciclosporin is a calcineurin inhibitor that inhibits 
T-cell-dependent immune responses. It has a rapid onset of action 
with significant improvement in disease severity often seen within 
a few weeks. However, relapse is commonly seen after treatment 
withdrawal. Methotrexate is a folic acid antagonist, but its exact 
mechanism of action in inflammatory diseases, including AD, is 
not fully understood. It has a relatively slow onset of action, like 
azathioprine. The latter exerts its anti-inflammatory effects by 
inhibition of de novo purine synthesis leading to impaired 
leucocyte proliferation. Anecdotally, azathioprine and methotrex-
ate have the potential to alter the natural history of the disease 
and induce long-term remission, although there is currently no 
RCT evidence to confirm this14–16. Mycophenolate mofetil blocks 
de novo guanine synthesis via the inhibition of inosine monophos-
phate dehydrogenase leading to impaired leucocyte proliferation. 
The safety profiles of azathioprine and ciclosporin in particular 
are of concern. Nephrotoxicity and hypertension are the most 
significant side effects of ciclosporin. As a result, the United 
States Food and Drug Administration recommends limiting its 
continuous use to one year in psoriasis patients17. Azathioprine can 
cause myelosuppression and carries an increased risk of infection, 
lymphoma, and non-melanoma skin cancer18–22. Methotrexate and 
mycophenolate mofetil are considered relatively safe medications, 
but long-term data from AD cohorts are missing at present. In 
practice, even when a conventional agent is working well in AD, 
most clinicians feel that these agents cannot be used for years, 
particularly because of the long-term risk of malignancy. The 
development of novel agents, with improved long-term safety, is 
therefore essential.
Novel systemic atopic dermatitis treatments
Thanks to our enhanced understanding of the complex immu-
nological processes in AD skin, there are now many promising 
treatment targets (Figure 1). Dupilumab is an interleukin (IL)-4 
receptor A-antagonist that inhibits IL-4 and IL-13 signalling and 
has been approved in Europe and the United States for the treatment 
of adults with moderate-to-severe AD. Clinical trials are under-
way in children. In addition to dupilumab, the IL-13 inhibitors 
tralokinumab and lebrikizumab and the IL-31 receptor monoclonal 
antibody nemolizumab have also demonstrated good potential 
in clinical trials. Fezakinumab, a monoclonal antibody against 
IL-22, was effective in the treatment of patients with severe AD 
in a recent phase 2 trial. Janus kinase (JAK) inhibitors are used 
to treat a range of inflammatory diseases, and data demonstrating 
their efficacy in AD are now also emerging.
Indirect comparison of atopic dermatitis systemic 
treatments
As there is a paucity of direct head-to-head trial data comparing 
treatments in AD, we have indirectly compared the performance 
of these drugs using data from published RCTs. In our analysis, 
we have included both blinded and open-label extension RCTs 
that were published up until 30 September 2018 and report effi-
cacy and safety data of one or more systemic immunomodulatory 
treatments for moderate-to-severe AD. We have included only the 
conventional systemic RCTs in which the most commonly used 
conventional treatments were tested: ciclosporin, methotrexate, 
azathioprine, and mycophenolate mofetil. We included only trials 
that used a validated severity measure, such as the Eczema Area 
and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD) 
index, the Six Area Six Sign Atopic Dermatitis (SASSAD) 
severity score, or the Patient Oriented Eczema Measure (POEM).
Overview of included randomised controlled trials
We included 33 trials (Table 1). Most of the trials testing 
conventional systemic agents were small, and a single phase 3 
dupilumab trial enrolled more patients than all the included 
conventional systemic trials23. A total of 12 RCTs were head- 
to-head comparisons and 21 were placebo-controlled trials. The 
majority (85.7%, 12/14) of the conventional systemic agent trials 
were head-to-head comparisons, while there are currently no 
head-to-head trials including novel AD treatments. A diverse range 
of primary endpoints was used across these studies (Figure 2).
Treatment effectiveness: physician-assessed severity 
measures
Different clinical severity score endpoints were reported across 
the trials (Supplementary Figure 1). Many trials did not report 
the same scores, even as secondary or experimental endpoints, 
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Figure 1. Atopic dermatitis pathogenesis and drug targets of novel systemic therapies. Novel systemic therapies target immune 
mediators in atopic dermatitis. Mepolizumab is a monoclonal antibody to interleukin-4 (IL-4). Omalizumab is a monoclonal anti- 
immunoglobulin E (IgE) antibody. Dupilumab is an IL-4 receptor A-antagonist that inhibits IL-4 and IL-13 signalling. Lebrikizumab 
and tralokinumab are monoclonal antibodies that bind to IL-13. Ustekinumab binds to the shared p40 subunit of IL-12 and IL-23 to 
regulate T helper type 1 (Th1) and Th17 pathways. Nemolizumab is a monoclonal antibody against IL-31 receptor A. Fezakinumab is 
an IL-22 antagonist. Baricitinib is a Janus kinase 1 (JAK1) and JAK2 inhibitor. DC, dendritic cell; ILC2, type 2 innate lymphoid cell; LC, 
Langerhans cell; S. aureus, Staphylococcus aureus; TSLP, thymic stromal lymphopoietin.
making indirect comparison of some treatments very diffi-
cult. In some cases, the scales of the same score differed across 
trials, thus further complicating clinical effectiveness compari-
sons. For instance, the Investigator’s Global Assessment (IGA) 
score was reported in 22 trials, but some used a five-point Likert 
scale while others used a six-point scale. Some trials reported the 
objective SCORAD score, whereas others published the full 
composite SCORAD index, which includes patient-reported 
pruritus and sleep disturbance.
We compared the mean percentage change from baseline for EASI 
and SCORAD for each of the systemic treatments where these 
data were available (Figure 3a and 3b, Supplementary Figure 2a 
and 2b). We calculated a mean placebo response using pooled 
data from all novel systemic therapy RCTs. This indirect compari-
son suggests that ciclosporin at a dose of 2.7–5 mg/kg/day in the 
short-term and methotrexate and azathioprine in the longer term 
may perform as well as many of the novel systemic agents. The 
superior performance of dupilumab compared with ciclosporin 
(2.5–5 mg/kg/day) in terms of EASI is consistent with another 
indirect comparison in which logistic regression modelling 
was used to predict the EASI responses to these treatments24. 
However, drug dosing is important, and an indirect comparison 
of effectiveness, as measured by SCORAD reduction induced 
by these agents, suggests that ciclosporin at a dose of 5 mg/kg/day 
may be as effective as dupilumab at least for short-term disease 
control.
Treatment effectiveness: patient-reported severity 
measures
A wide range of patient-assessed measures was reported across 
the included trials (Supplementary Figure 3). Nemolizumab and 
dupilumab appear to be superior in improving pruritus compared 
to the other treatments (Figure 4), although the available pruritus 
score data are very limited, in particular for conventional systemic 
agents.
Treatment effectiveness: quality of life
The Dermatology Life Quality Index (DLQI) was the most widely 
reported measure of quality of life, although there were several 
other scores reported across the trials (Supplementary Figure 4). 
Baricitinib and dupilumab appear to perform best at improving 
quality of life (Figure 5), although DLQI was not reported in most 
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Table 1. Summary of included randomised controlled trials.
Author Year Intervention n Study 
duration 
(weeks)
Harper et al.25 2000 Ciclosporin burst versus 
continuous therapy
40 52
Granlund et al.26 2001 Ciclosporin versus UVAB 
phototherapy
38 8
Pacor et al.27 2004 Ciclosporin versus tacrolimus 30 8
Bemanian et al.28 2005 Ciclosporin versus intravenous 
immunoglobulin
14 12
Schmitt et al.29 2010 Ciclosporin versus prednisolone 38 6
El-Khalawany et al.30 2013 Ciclosporin versus methotrexate 40 12
Koppelhus et al.31 2014 Ciclosporin versus extracorporeal 
photopheresis
20 30
Jin et al.32 2015 Ciclosporin versus ciclosporin + 
glucosamine
38 8
Kim et al.33 2016 Ciclosporin versus ciclosporin + 
topical therapy
60 24
Goujon et al.34 2017 Ciclosporin versus methotrexate 97 24
Berth-Jones et al.35 2002 Azathioprine versus placebo 27 12
Meggitt et al.36 2006 Azathioprine versus placebo 41 12
Schram et al.37 2011 Azathioprine versus methotrexate 42 12
Gerbens et al.14 2018 Azathioprine versus methotrexate 35 260
Oldhoff et al.38 2005 Mepolizumab versus placebo 43 2
Iyengar et al.39 2013 Omalizumab versus placebo 8 24
Beck et al.40 2014 Dupilumab versus placebo 30 4
Beck et al.40 2014 Dupilumab versus placebo 37 4
Beck et al.40 2014 Dupilumab versus placebo 109 12
Beck et al.40 2014 Dupilumab + topical 
glucocorticoids versus placebo
31 4
Thaçi et al.41 2016 Dupilumab versus placebo 379 16
Simpson et al.23 2016 Dupilumab versus placebo 671 16
Simpson et al.23 2016 Dupilumab versus placebo 708 16
Blauvelt et al.42 2017 Dupilumab versus placebo 740 52
de Bruin-Weller et al.43 2018 Dupilumab versus placebo 390 16
Khattri et al.44 2017 Ustekinumab versus placebo 33 33
Saeki et al.45 2017 Ustekinumab versus placebo 79 12
Ruzicka et al.46 2017 Nemolizumab versus placebo 264 12
Kabashima et al.47 2018 Nemolizumab versus placebo 191 64
Wollenberg et al.48 2018 Tralokinumab versus placebo 204 12
Guttman-Yassky et al.49 2018 Fezakinumab versus placebo 60 10
Guttman-Yassky et al.50 2018 Baricitinib versus placebo 124 16
Simpson et al.51 2018 Lebrikizumab versus placebo 209 12
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Figure 2. Primary end points of included trials. The diverse range of primary endpoints reported across included randomised controlled 
trials. EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; PGA, Physician’s Global Assessment; SASSAD, Six 
Area Six Sign Atopic Dermatitis; SCORAD, Scoring Atopic Dermatitis; VAS, visual analogue scale.
of the conventional systemic trials, thus precluding many of these 
treatments from the comparison.
Treatment effectiveness: long-term disease control
Regarding long-term disease control, there are very few data 
available on the performance of conventional systemics and no data 
beyond 64 weeks for the novel systemic agents. Dupilumab and 
nemolizumab appear to be superior to other treatments up to one 
year (Figure 6). Haeck et al. showed that mycophenolate sodium 
is also effective at maintaining remission for up to one year, after 
remission was induced with a six-week course of ciclosporin52. 
A five-year follow up study comparing methotrexate and aza-
thioprine was recently published and suggests good long-term 
effectiveness for both, but patient numbers in each study arm were 
small14. The extension study SOLO-CONTINUE (NCT02395133) 
will provide even longer-term effectiveness data for dupilumab. 
Importantly, data on clinical effectiveness in terms of inducing 
and maintaining disease remission off treatment are lacking for 
any systemic therapy, although anecdotally this has been seen for 
methotrexate and azathioprine in particular14–16.
Drug safety profiles
Short-term safety
To compare the tolerability and safety of AD systemic treatments, 
we have calculated the incidence rates per participant per week for 
AEs and serious AEs (SAEs), as these were defined in individual 
trials (n = 26). Seven trials either did not provide any AE data 
or did not provide the data in a form that enabled incidence rate 
calculation. This highlights the lack of standardisation in safety 
reporting in clinical trials, limiting robust comparisons across 
trials. Table 2 summarises the available safety data from the 
included studies, showing high variability in the incidence rates 
reported for the conventional systemic agents. This is most likely 
due to the small study size and short duration of the included 
studies. If participant numbers are small in a RCT, then there 
may be misleadingly low AE reporting, falsely suggesting a more 
favourable drug safety profile than is seen in clinical practice.
Long-term safety
Although pre-clinical data suggest that novel systemics may be 
safer than conventional agents, data on the long-term safety of 
both systemics in AD populations are limited53. Although most 
cases of immunosuppression-related malignancy occur in the 
context of organ transplantation, studies of patients with 
inflammatory bowel disease have found an increased risk of 
lymphoma and non-melanoma skin cancer in those treated with 
azathioprine19–22. Furthermore, there are cases of methotrexate-
associated lymphoproliferative disorders, which resolve after 
withdrawal of the drug, seen in adults with autoimmune diseases, 
such as rheumatoid arthritis54,55. However, these patients have 
different co-morbidities and take additional medications to those 
taken by AD patients, which may play a role in these associations. 
Cases of malignancy have been reported in RCTs of JAK inhibi-
tors in patients with rheumatoid arthritis, and additional data from 
long-term follow up of patient cohorts is needed to determine the 
true malignancy risk for JAK inhibitors in AD56.
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Figure 3. Treatment effectiveness: physician-assessed severity measures. Eczema Area and Severity Index (EASI) (a) and Scoring 
Atopic Dermatitis (SCORAD) (b) mean percentage change from baseline up to 16 weeks for systemic agents for which these data 
were reported. MTX, methotrexate.
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Figure 4. Treatment effectiveness: patient-reported severity measures. Mean percentage change from baseline in pruritus visual analogue 
score (VAS) and pruritus numerical rating scale (NRS) for systemic agents for which these data were reported.
Figure 5. Treatment effectiveness: quality of life. Dermatology Life Quality Index (DLQI) mean percentage change from baseline for 
systemic agents for which these data were reported.
·½»ʿÅ¼ʸʻ
	ʸʷʷʷ»É»·È¹¾ʹʷʸˀƑʿƺ	ʸʷʷʷ	·¹ËÂÊÏ»ÌƻƓʸʺʹ·ÉÊËÆº·Ê»ºƓʷʸ	ʹʷʸˀ
Table 2. Summary of adverse events.
Systemic 
agent
SAE incidence 
rate per patient 
week (%)
AE incidence rate per 
patient week (%)
Common AEs (clinical trial incidence of 1/100)
Ciclosporin 0–2.2 0–20.8 Serum creatinine increase, hypertension, GI upset, infections, skin 
infections, headache, fatigue, cramps, paraesthesia, lower limb 
oedema, hypertrichosis, gingival hyperplasia, anaemia, leukopenia, 
pancytopenia, thrombocytopenia, ESR increase, liver enzyme increase, 
magnesium decrease, fever, malaise, AD exacerbation, dyslipidaemia, 
tremor, flushing, metallic taste
Methotrexate 0.19 9.8–23.5 GI upset, infections, liver enzyme increase, skin infections, AD 
exacerbation, anaemia, leukopenia, pancytopenia, fatigue, headache, 
renal impairment, fever, malaise
Azathioprine 0.03 3–22.9 GI upset, URTI, LRTI, fatigue, light-headedness, malaise, headache, 
folliculitis, skin infections, lymphopenia, neutropenia, liver enzyme 
increase, AD exacerbation
Mycophenolate 
mofetil
0 4.2 Nausea, headache, fatigue, paraesthesia, muscle ache, infections, 
serum creatinine increase, leukopenia, liver enzyme increase, 
magnesium decrease
Dupilumab 0–0.55 6.4–21.6 Nasopharyngitis, headache, URTI, injection site reactions, 
conjunctivitis, AD exacerbation, skin infections, herpes viral infections
Nemolizumab 0.18 6.6 Nasopharyngitis, AD exacerbation, serum CK increase, URTI, 
headache, peripheral oedema, impetigo, injection-site reactions
Ustekinumab 0 2.3–2.4 Nasopharyngitis, AD exacerbation
Fezakinumab 0.42 2.25 Viral URTI
Lebrikizumab Not reported 
(3.2% of patients 
had q1 SAE over 
20-week study)
Not reported 
(67% of patients had q1 
AE over 20-week study)
Infections, skin infections, HSV and HZV infections, 
conjunctivitis, injection site reactions
Baricitinib 0.08% Not reported 
(59% of patients had q1 
AE over 16-week study)
Headache, serum CK increase, AD exacerbation, nasopharyngitis, 
cellulitis, infections
Tralokinumab Not reported 
(3.3% of patients 
had q1 SAE over 
12-week study)
Not reported 
(66% of patients had q1 
AE over 12-week study)
Nasopharyngitis, URTI, headache, AD exacerbation, injection site 
reactions, arthralgia, syncope
AD, atopic dermatitis; AE, adverse event; CK, creatine kinase; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; HSV, herpes simplex virus; HZV, herpes 
zoster virus; LRTI, lower respiratory tract infection; SAE, serious adverse event; URTI, upper respiratory tract infection.
Figure 6. Treatment effectiveness: long-term disease control. Scoring Atopic Dermatitis (SCORAD) mean percentage change from 
baseline for systemic agents for which these data were reported in at least one trial that was one year or longer in duration.
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Cost-effectiveness
Despite novel systemic agents’ promising clinical effectiveness, 
there is no guarantee that they will be affordable for use within 
collectively funded healthcare systems. Given that innovations in 
medicine often impose additional costs when compared to usual 
care, many healthcare systems around the world now require 
robust evidence demonstrating that a drug therapy is cost-effective 
to receive approval for use in clinical practice57,58. As such, it 
is important to consider the evidence needed to develop a cost- 
effectiveness analysis when formulating data collection strate-
gies for the evaluation of novel systemic treatments. In many 
countries—including England, Canada, and Australia— 
cost-effectiveness studies quantify changes in patient health, 
using the quality-adjusted life year (QALY), which combines 
mortality and morbidity effects in a single outcome measure59–61. 
Morbidity effects are typically captured using a preference-based 
measure of health-related quality of life (HRQoL), such as the 
EQ-5D instrument62. In addition, data on healthcare resource use 
and unit costs are needed to calculate the expected healthcare 
costs associated with the alternative treatments being compared.
A recent systematic review by McManus et al. identified 
24 cost-effectiveness studies evaluating interventions for the 
treatment and prevention of AD63. One of the key findings in 
this review was the observed variability in the methods used to 
combine different forms of evidence (e.g. response rates, HRQoL 
effects, and resource use), also known as models. In other disease 
areas, such as rheumatoid arthritis and psoriatic arthritis64, efforts 
have been made to reach a consensus on the preferred model-
ling approach and, as a consequence, standardise the evidence 
requirements. Similar efforts to establish a preferred modelling 
approach in the context of AD not only would provide a benchmark 
against which studies could be assessed but also could be used to 
inform future data collection strategies.
Another important finding of the systematic review was that the 
time horizons under examination in many of the studies were 
of insufficient duration. Ideally, the time horizon for any given 
cost-effectiveness study should reflect the length of time over 
which the expected costs and QALYs are likely to differ between 
alternative treatment strategies65. Although a challenging propo-
sition given that the follow up of patients even in observational 
studies continues for only three to five years, the recent appraisal of 
dupilumab by NICE demonstrates that observational evidence can 
be used in addition to RCT data to inform the cost-effectiveness 
analysis of patients66. Partly based on this health economic 
analysis, NICE has recommended dupilumab as an option for 
treating moderate-to-severe AD in adults where the disease has 
not responded to at least one conventional systemic therapy or 
where these are contraindicated or not tolerated66. Interestingly, the 
economic model considered as part of the NICE appraisal com-
pared dupilumab with topical therapy as best supportive care. The 
rationale for this was that dupilumab would be positioned after 
conventional systemics in the treatment pathway for AD, at 
which point the only other treatment option for patients would be 
topical therapy67. Topical therapy might indeed be considered 
best supportive care once a patient has failed on all conventional 
systemics; however, this was not the population of patients studied 
in the dupilumab trials. Indeed, only one trial, LIBERTY-CAFÉ, 
required participants to have a prior history of ciclosporin use 
(or contraindication). It is likely that the effectiveness of topical 
treatment varies in different populations and would be expected 
to be lower in a population of patients with AD who have 
failed multiple systemic treatments compared to those who are 
systemic treatment naïve. A cost-effectiveness model for novel 
agents should therefore be compared to conventional systemic 
treatment as best supportive care, even if this is challenging 
given the current lack of data on the cost-effectiveness of 
conventional systemics.
The formation of the UK–Irish Atopic eczema Systemic Therapy 
Register (A*STAR) and other national AD registers within the 
international TREatment of ATopic eczema registry taskforce 
(TREAT) represents an important milestone in the collection of 
data that can be used to inform cost-effectiveness studies for the 
evaluation of novel AD therapies68,69. These treatment registers will 
be an important data source for the development of future appraisal 
submissions to regulatory bodies, such as NICE in the UK, 
given that they collect longitudinal disease severity, quality of 
life, and healthcare resource use data for every patient recruited 
and compare conventional and novel therapies alike.
Indirect comparison method limitations
The indirect comparison of clinical effectiveness, safety data, 
and cost-effectiveness drawn from different studies, as presented 
here, has important limitations. Such comparisons lose the ben-
efits derived from randomisation, such as the balancing of effect 
modifiers across treatment groups at baseline. Whilst direct com-
parisons from individual studies may have a low risk of bias 
(i.e. high internal validity), the inferences drawn from compari-
sons between studies must be considered observational data and 
are therefore at higher risk of bias. For example, if the baseline 
characteristics of the trial participants, such as disease severity, 
differ, then it is difficult to compare a change in disease sever-
ity across trials even where the same disease severity measure 
was used. Other study design differences will additionally 
impact on treatment effectiveness, such as the use of concomitant 
topical corticosteroids.
Where do we go from here?
Further head-to-head active comparator studies are needed, such as 
the ongoing TREatment of severe Atopic eczema Trial (TREAT), 
which compares ciclosporin and methotrexate in children with 
moderate-to-severe AD70. Such studies need to use validated 
outcome measures that are harmonised to allow for comparisons 
to be made across studies. The Harmonising Outcome Measures 
for Eczema (HOME) initiative is an international effort towards a 
core outcome set for clinical trials in AD that will help to facilitate 
this71. Whilst not a current aim of the HOME initiative, reporting 
would also be useful.
Recognising that randomised controlled trial data directly 
comparing active treatments will always be limited, network meta-
analysis (NMA) will be helpful in plugging this evidence gap. 
NMA is an approach whereby direct and indirect data can be 
combined into a single statistical model that takes into account 
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variations between studies and where the assumptions around the 
similarities between studies can be evaluated72.
Although novel systemic agents may not vastly improve the clinical 
effectiveness outcomes in AD, they have the potential to address 
the more pressing clinical issue of short- and long-term AEs sec-
ondary to AD treatment. The limited duration of clinical trials, 
relatively small sample sizes with respect to safety outcomes, and 
issues around the generalisability of their findings to the wider 
patient population mean that data from large ‘real-world’ studies, 
such as registers and electronic health records, will play an 
important role in providing evidence to support clinical decision- 
making. Standardised AE reporting is also needed as we approach 
an era where safety and tolerability may become more of 
a differentiator of treatments than clinical effectiveness.
Conclusion
Novel biologic and small molecule agents provide great prom-
ise for patients with moderate-to-severe AD. While the clinical 
effectiveness data from these placebo-controlled RCTs are 
promising, important factors in addition to short- and long-term 
treatment effectiveness need to be considered, such as drug safety 
and cost-effectiveness as well as the ability of a drug to alter 
the natural history of AD. While evidence generation through 
head-to-head trials would be the preferred route, such trials are 
likely to remain low in number. Treatment registers and NMA 
provide important additional tools to better inform evidence-based 
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Supplementary Figure 1. Physician-assessed severity score end points of included trials.
Different clinical severity score endpoints were reported across included randomised controlled trials. Many trials did not report the same 
scores, making indirect comparison of some treatments very difficult. EASI, Eczema Area and Severity Index; IGA, Investigator’s Global 
Assessment; SASSAD, Six Area Six Sign Atopic Dermatitis; SCORAD, Scoring Atopic Dermatitis.
Click here to access the data
Supplementary Figure 2. Treatment effectiveness: physician-assessed severity measures.
Eczema Area and Severity Index (EASI) (a) and Scoring Atopic Dermatitis (SCORAD) (b) mean percentage change from baseline up to 64 
weeks for systemic agents for which these data were reported. MTX, methotrexate.
Click here to access the data
Supplementary Figure 3. Treatment effectiveness: patient-reported severity measures.
The number of included trials reporting patient-reported severity measures. HADS, Hospital Anxiety and Depression Scale; NRS, numeri-
cal rating scale; POEM, Patient Oriented Eczema Measure; RCT, randomised controlled trial; SCORAD, Scoring Atopic Dermatitis; VAS, 
visual analogue scale.
Click here to access the data
Supplementary Figure 4. Treatment effectiveness: quality of life.
The number of included trials reporting quality of life measures. AD, atopic dermatitis; cDLQI, children’s Dermatology Life Quality Index; 
DLQI, Dermatology Life Quality Index; RCT, randomised controlled trial; VAS, visual analogue scale.
Click here to access the data
treatment decisions made by physicians, patients, and regulatory 
bodies alike. We have entered an exciting era in AD therapeutics 
but need to travel a much longer journey before the promise of a 
therapeutic revolution becomes a reality.
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